<DOC>
	<DOCNO>NCT00048334</DOCNO>
	<brief_summary>This phase I study evaluate experimental drug Romidepsinin patient advance cancer . The study : 1 ) determine well patient tolerate Romidepsin ; 2 ) measure blood level Romidepsin treatment ; 3 ) analyze cellular molecular effect drug ; 4 ) determine Romidepsin shrink tumor . Romidepsin show kill cancer cell grow laboratory shrink tumor animals various tumor type . In preliminary study , several patient type lymphoma one patient kidney cancer respond treatment . Patients 18 year age old advanced cancer ( exclude acute leukemia ) may eligible study . Candidates screen medical history physical examination , x-rays CT scan , blood urine test . Patients thyroid cancer may also magnetic resonance imaging ( MRI ) . This test use magnetic field instead x-rays obtain image body organ tissue . Participants receive three infusion Romidepsin administer intravenous line 4 hour day 1 , 3 5 21-day treatment cycle . The intravenous line catheter ( plastic tube ) place vein may peripheral line , insert vein arm , central line , tube place skin chest neck major vein . Patients hospitalize first 6 day first cycle monitor heart rate . Those tolerate treatment well may continue outpatient . In addition drug therapy , participant undergo follow procedure : - Blood test : Small amount blood drawn frequently first five day treatment measure Romidepsin level see body use excrete drug . A heparin lock ( indwell device keep vein open ) may put vein prevent need repeat needle stick . - Biopsies ( removal small sample tumor tissue ) : Tumors accessible may biopsied start study different time treatment . Biopsies do three time per cycle , nine biopsy do within year . The sample examine effect Romidepsin protein control way cell divide stay alive . - Apheresis : This procedure do collect white blood cell cancer cell research . Blood collect needle arm vein direct machine separate component centrifugation ( spin ) . The white cell remove red cell return patient needle another needle arm . - Scans x-ray : Imaging study usually do start treatment . Some repeat every 2 cycle ( 6 week ) , end patient 's participation study . The test may include chest x-ray , plain x-rays affected bone , CT scan chest , abdomen , pelvis , bone scan , MUGA scan ( special X-ray heart ) echocardiogram ( ultrasound heart ) test heart function study . MRI positron emission tomography ( PET ) scan may also do detect tumor . PET scan use small amount radioactive substance inject vein . The radioactivity detect special camera scan detect cancer cell . - Other test include electrocardiogram ( record electrical activity heart ) dose depsipeptide . Eye exams do vision change doctor recommend eye test .</brief_summary>
	<brief_title>Depsipeptide Treat Thyroid Other Advanced Cancers</brief_title>
	<detailed_description>BACKGROUND : Romidepsin ( NSC 630176 , FR901228 , FK228 , formerly refer depsipeptide ) histone deacetylase inhibitor potent cytotoxic activity human tumor cell line vivo efficacy human tumor xenograft murine tumor ( 1-3 ) . Laboratory study suggest long exposure non-toxic dos romidepsin enhance molecular effect great degree short toxic dos rapidly cause cell death . NIS responsible enable uptake RAI thyroid cancer , decrease level tumor resistant refractory RAI therapy . Our group demonstrate NIS expression upregulated romidepsin , result increased sensitivity RAI . OBJECTIVES : To determine MTD romidepsin administer day 1 , 3 5 . To examine effect multi-day regimen romidepsin surrogate marker expression molecular target . To determine whether thyroid cancer detectable uptake RAI detectable uptake treatment . ELIGIBILITY : - Age 18 - Evaluable disease - Performance status ECOG 0-2 - Excluding patient pregnant , HIV positive , CNS metastasis , acute leukemia - Left ventricular ejection fraction within normal limit . Additional cardiac criterion note protocol DESIGN : - Phase I - Romidepsin administer 4-hour intravenous infusion day 1 , 3 5 - Dose escalation - Enrollment additional cohort 10 patient thyroid cancer MTD</detailed_description>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients must histologic cytologic confirmation cancer ( exclude acute leukemia ) know standard therapy capable extend life expectancy . 2 . Patients must : Be age great equal 18 year . Have evaluable disease . Have performance status ECOG 02 . Have serious intercurrent illness medically control life expectancy great 12 week . Give write informed consent . Be willing return National Cancer Institute followup . Female patient childbearing potential must negative pregnancy test within 1 week must use effective contraception ( hormonal barrier method ) treat protocol . 3 . Laboratory value : Within 7 day prior registration : absolute neutrophil count great equal 1000/microL , platelet great equal l00,000/microL , bilirubin ( total direct ) less equal 1.5x upper limit normal , AST le equal 3x upper limit normal , creatinine less equal to1.5x upper limit normal , documented creatinine clearance great equal 60mL/min . Within 4 week registration : ejection fraction great 50 % echocardiogram cardiac MRI , 45 % MUGA scan . 4 . Criteria cohort patient RAI refractory nonmedullary thyroid cancer enrol MTD define : Nonmedullary thyroid carcinoma . progressive disease follow total neartotal thyroidectomy RAI therapy . Documented evidence , minimally ( faint ) , RAI uptake RAI whole body scan . RAI therapy within 3 month prior study entry . history administration IV iodinate contrast large iodine load ( i.e . CT , amiodarone , SSKI ) previous 3 month . 24 hr urinary iodine value less equal to150 microg/day . EXCLUSION CRITERIA 1 . Patients unconfirmed diagnosis exclude . 2 . Prior concurrent malignancy curatively treat . 3 . Current previous CNS metastasis . 4 . Chemotherapy within 4 week , 6 week nitrosoureas mitomycin C , 8 week UCN01 . 5 . HIV seropositivity . 6 . Pregnant breastfeeding patient . 7 . Uncontrolled infection . 8 . Patients follow cardiac risk factor exclude study : Patients know cardiac abnormality : Congenital long QT syndrome QTc interval great 480 millisecond Patients myocardial infarction within 12 month study entry . Patients active coronary artery disease , e.g . angina define Canadian Class IIIV Patients ECG record screen show evidence cardiac ischemia ( ST depression great equal 2 mm ) . Any patient coronary artery disease suspect referred cardiology consultation active myocardial ischemia demonstrate , patient exclude . If noninvasive imaging study equivocal , may necessary proceed coronary angiography . Patients congestive heart failure meet NYHA Class II IV definition and/or ejection fraction le 45 % MUGA scan less 50 % echocardiogram and/or MRI . Patients history sustain VT , VF , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) . Patients history arrhythmia Holter monitoring evaluation cardiology . Patients dilate , hypertrophic , restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) . Patients leave ventricular hypertrophy discuss Principal Investigator Study Chairman . Patients uncontrolled hypertension , i.e . SBP great equal 160 mm Hg DBP great equal 95 mm Hg . Patients cardiac arrhythmia require antiarrhythmic medication beta blocker calcium channel blocker . Patients digitalis discontinue exclude study . Patients Mobitz II second degree heart block pacemaker . Patients first degree Mobitz I second degree heart block , bradyarrhythmias sick sinus syndrome require Holter monitoring evaluation cardiology . Patients cardiac disease may exclude discretion PI follow consultation cardiology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 7, 2014</verification_date>
	<keyword>Histone Acetylation</keyword>
	<keyword>Cancer</keyword>
</DOC>